Immunovia AB 2019 AR2
The report highlights Immunovia's progress during the 2019 financial year, particularly the successful completion of its Commercial Test Model Study for IMMray PanCan-d, which achieved 95 percent accuracy in detecting early-stage pancreatic cancer. The company focused on preparing for the launch of this blood-based test in the United States, scheduled for the third quarter of 2020. Additionally, Immunovia expanded its prospective clinical studies program, including PanFAM-1, PanDIA-1, and PanSYM-1, involving over 10,000 individuals across 24 cancer centers. The company also advanced its early-stage programs in lung cancer and rheumatoid arthritis, while maintaining a strong commitment to gender equality, ranking 45th in the Albright Report.
Company: Immunovia AB
Sector: Professional & technical services
Country: Sweden
Year: 2019
Type: AR2
Pages: 80
Back to company
Immunovia AB
Annual Report
The report highlights Immunovia's progress during the 2019 financial year, particularly the successful completion of its Commercial Test Model Study for IMMray PanCan-d, which achieved 95 percent accuracy in detecting early-stage pancreatic cancer. The company focused on preparing for the launch of this blood-based test in the United States, scheduled for the third quarter of 2020. Additionally, Immunovia expanded its prospective clinical studies program, including PanFAM-1, PanDIA-1, and PanSYM-1, involving over 10,000 individuals across 24 cancer centers. The company also advanced its early-stage programs in lung cancer and rheumatoid arthritis, while maintaining a strong commitment to gender equality, ranking 45th in the Albright Report.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Published
Mar 20, 2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees